June 9, 2008 - Hologic Inc. said today that it has signed a definitive agreement to acquire Third Wave Technologies Inc. for a purchase price of $11.25 per share, or approximately $580 million in value, a transaction anticipated to be completed in the third quarter of 2008, said Hologic.
Third Wave develops and markets molecular diagnostic reagents for a wide variety of DNA and RNA analysis applications based on its proprietary Invader chemistry. The company’s current clinical diagnostic offerings consist of products for conditions such as Cystic Fibrosis, Hepatitis C, cardiovascular risk and other diseases. The company recently submitted to the FDA premarket approval (PMA) applications for two human papilloma virus, or HPV, tests. These submissions are based on a successfully completed clinical trial.
For more information: www.hologic.com, www.twt.com
May 15, 2024 
